Literature DB >> 16325180

The alpha-synuclein mutation E46K promotes aggregation in cultured cells.

Neeraj Pandey1, Robert E Schmidt, James E Galvin.   

Abstract

Parkinson's disease (PD) is characterized by the polymerization of wild-type (WT) or mutant alpha-synuclein (AS) into aggregates and fibrils, which are observed as Lewy bodies (LBs) and Lewy neurites (LNs) in PD patients. However, inability to demonstrate aggregation in many cell culture systems is a major drawback for effective in vitro modeling of AS aggregation. Utilizing PCR-based cloning approach, we generated A30P, A53T, and the recently reported E46K encoding mutation in the KTKEGV repeat region of AS gene. While cloning E46K mutant, a glycine deletion mutation (E46KDeltaG) adjacent to the intended lysine mutation was serendipitously generated. Expression of mutant constructs and green fluorescent protein (GFP)-tagged mutant constructs in catecholaminergic SH-SY5Y (5Y) cells revealed 40% of AS-E46KDeltaG and 18% of AS-E46K transfected cells formed aggregates as compared to 12% in AS-A53T, 6% in AS-WT, and 2% in AS-A30P transfected cells. Western blot analysis demonstrated the formation of high molecular weight AS aggregates. Electron microscopic analysis of 5Y cells expressing the E46K and E46KDeltaG mutants demonstrated two distinct kinds of inclusions: Type I, which showed dense granular profile; and Type II, which were largely membranous vacuolar inclusions without granular material. These two inclusions are reminiscent of Lewy bodies and pale bodies observed in PD postmortem brain samples. Our results demonstrate that mutations in 4th KTKEGV repeat lead to higher propensity of aggregation of AS compared to other mutants.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325180     DOI: 10.1016/j.expneurol.2005.10.019

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  42 in total

1.  ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import.

Authors:  Quan Li; Christine Vande Velde; Adrian Israelson; Jing Xie; Aaron O Bailey; Meng-Qui Dong; Seung-Joo Chun; Tamal Roy; Leah Winer; John R Yates; Roderick A Capaldi; Don W Cleveland; Timothy M Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  Coupling of the non-amyloid-component (NAC) domain and the KTK(E/Q)GV repeats stabilize the α-synuclein fibrils.

Authors:  Liang Xu; Ruth Nussinov; Buyong Ma
Journal:  Eur J Med Chem       Date:  2016-01-25       Impact factor: 6.514

3.  Definition of a molecular pathway mediating α-synuclein neurotoxicity.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

4.  Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated α-Synuclein-selective Autophagic Degradation.

Authors:  Manel Dahmene; Morgan Bérard; Abid Oueslati
Journal:  J Biol Chem       Date:  2017-01-30       Impact factor: 5.157

5.  The α-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure.

Authors:  David R Boyer; Binsen Li; Chuanqi Sun; Weijia Fan; Kang Zhou; Michael P Hughes; Michael R Sawaya; Lin Jiang; David S Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-03       Impact factor: 11.205

6.  The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity.

Authors:  Ossama Khalaf; Bruno Fauvet; Abid Oueslati; Igor Dikiy; Anne-Laure Mahul-Mellier; Francesco Simone Ruggeri; Martial K Mbefo; Filip Vercruysse; Giovanni Dietler; Seung-Jae Lee; David Eliezer; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

7.  Effects of Mutations on the Reconfiguration Rate of α-Synuclein.

Authors:  Srabasti Acharya; Shreya Saha; Basir Ahmad; Lisa J Lapidus
Journal:  J Phys Chem B       Date:  2015-12-04       Impact factor: 2.991

8.  Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.

Authors:  Min S Wang; Shanta Boddapati; Sharareh Emadi; Michael R Sierks
Journal:  BMC Neurosci       Date:  2010-04-30       Impact factor: 3.288

9.  The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein.

Authors:  Jihoon Kim; Ryuichi Harada; Masaki Kobayashi; Natsuki Kobayashi; Koji Sode
Journal:  Mol Neurodegener       Date:  2010-05-20       Impact factor: 14.195

10.  Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy.

Authors:  Christina R Bodner; Alexander S Maltsev; Christopher M Dobson; Ad Bax
Journal:  Biochemistry       Date:  2010-02-09       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.